IL2 and metastatic melanoma: Similarly, early clinical studies testing IL-2-activated autologous NK cells for treatment of patients with metastatic melanoma, renal cell carcinoma, relapsed lymphoma, and metastatic breast cancer were ineffective (67, 68), suggesting that in autologous settings, inhibitory signals from self-MHC molecules in tumor cells are likely to suppress NK cell function in the absence of activating signals.